John Vincent Sanchez Orti | Biomarkers in Neurocognition | Young Scientist Award

Dr. John Vincent Sanchez Orti | Biomarkers in Neurocognition | Young Scientist Award

Dr. Joan Vicent Sánchez Ortí, Health research institute,  Spain.

Joan Vicent Sánchez Ortí is a Clinical Psychologist and Neuropsychologist currently working as a Research Technician at the Instituto de Investigación Sanitaria – INCLIVA. He is also a predoctoral researcher affiliated with CIBERSAM (Group 24, Universitat de València). His academic background includes a Bachelor’s degree in Psychology (2016), a Master’s in General Health Psychology (2019), and a Master’s in Basic and Applied Neurosciences (2021), all from Universitat de València. He is currently pursuing a Ph.D. in Medicine.

Profile

Google Scholar

Orcid

🧠 A Passion for Understanding the Mind

Joan Vicent Sánchez Ortí was born on August 6, 1994, with an innate curiosity about the complexities of human cognition. From an early age, he displayed a deep interest in psychology and neuroscience, which led him to pursue an academic path dedicated to unraveling the mysteries of the brain. His journey began at the Universitat de València, where he obtained his degree in Psychology in 2016. Motivated by his growing fascination with neuropsychology, he continued his studies, earning a Master’s in General Health Psychology in 2019 and a Master’s in Basic and Applied Neurosciences in 2021. His dedication to advancing medical science led him to enroll in an official Doctorate Program in Medicine at the same institution.

🏥 Bridging Psychology and Neuroscience in Professional Practice

Currently serving as a Neuropsychologist and Research Technician at the Health Research Institute (INCLIVA) in Spain, Joan Vicent plays a vital role in understanding cognitive impairments associated with severe mental disorders. His affiliation with the Biomedical Research Center in Mental Health Network (CIBERSAM) – Group 24 at the Universitat de València has allowed him to contribute significantly to groundbreaking studies. His expertise lies in assessing neurocognitive deficits, biomarkers, and epigenetic factors, aiming to enhance the diagnosis and treatment of psychiatric and neurological conditions.

🔬 Advancing Research in Neurocognitive Deficits and Mental Health

Joan Vicent’s research delves into the intricate connections between brain function, cognition, and mental health. His studies focus on identifying early biomarkers of cognitive decline, exploring epigenetic influences, and evaluating social functioning and quality of life in patients suffering from severe mental disorders. His contributions have been instrumental in improving the understanding of conditions such as schizophrenia, bipolar disorder, and neurodegenerative diseases, providing valuable insights for clinical interventions.

🏆 Recognized for Excellence in Neuroscience and Psychology

Through his commitment to scientific discovery, Joan Vicent has garnered recognition in the field of neuroscience and psychology. His contributions to neuropsychology and mental health research have positioned him as a promising figure in cognitive science. His work is widely acknowledged for its impact on the development of new therapeutic approaches and diagnostic techniques. With a strong academic and research background, he continues to be an influential voice in the study of cognitive impairment.

🌍 Impacting Lives Through Mental Health Research

Beyond academic achievements, Joan Vicent’s work has real-world implications, improving the quality of life for individuals facing cognitive challenges. His research contributes to developing more effective treatments, enhancing diagnostic accuracy, and fostering a better understanding of mental disorders. Through his role at INCLIVA and CIBERSAM, he actively collaborates with interdisciplinary teams, ensuring that his findings are translated into clinical practice, ultimately benefiting patients and healthcare professionals alike.

🚀 Paving the Way for Future Innovations in Neuropsychology

With a strong foundation in psychology, neuroscience, and medicine, Joan Vicent remains dedicated to pushing the boundaries of cognitive research. His ongoing studies aim to integrate cutting-edge techniques in neuroimaging, genetics, and artificial intelligence to refine the understanding of neurocognitive disorders. His ambition is to contribute to the development of personalized medicine, where treatments are tailored to an individual’s neurobiological and psychological profile, revolutionizing mental healthcare.

🔮 A Vision for a Healthier, Cognitively Resilient Future

Looking ahead, Joan Vicent Sánchez Ortí envisions a world where mental health is better understood, diagnosed, and treated with precision. His dedication to neuropsychology and cognitive research will continue to shape the future of mental healthcare, inspiring new generations of scientists and clinicians. As he advances in his career, his unwavering commitment to improving lives through research stands as a testament to his passion and perseverance in the field of neuroscience.

Publication

  • Manual motor speed dysfunction as a neurocognitive endophenotype in euthymic bipolar disorder patients and their healthy relatives. Evidence from a 5-year follow-up study
    P Correa-Ghisays, V Balanzá-Martínez, G Selva-Vera, J Vila-Francés, …
    2017

 

  • Grip Strength, Neurocognition, and social functioning in people With Type-2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia
    M Aliño-Dies, JV Sanchez-Orti, P Correa-Ghisays, V Balanzá-Martinez, …
    2020

 

  • Visual memory dysfunction as a neurocognitive endophenotype in bipolar disorder patients and their unaffected relatives. Evidence from a 5-year follow-up Valencia study
    P Correa-Ghisays, JV Sánchez-Ortí, R Ayesa-Arriola, E Setién-Suero, …
    2019

 

  • Specific metabolic syndrome components predict cognition and social functioning in people with type 2 diabetes mellitus and severe mental disorders
    JV Sanchez‐Orti, V Balanzá‐Martinez, P Correa‐Ghisays, G Selva‐Vera, …
    2022

 

  • Immune–Inflammatory Biomarkers Predict Cognition and Social Functioning in Patients With Type 2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and …
    M Garés-Caballer, JV Sánchez-Ortí, P Correa-Ghisays, …
    2022

 

  • Probiotic, prebiotic, synbiotic and fermented food supplementation in psychiatric disorders: A systematic review of clinical trials
    C Ribera, JV Sánchez-Ortí, G Clarke, W Marx, S Mörkl, …
    2024

 

  • Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: A 1-year follow-up study
    P Correa-Ghisays, JV Sanchez-Orti, V Balanza-Martinez, G Selva-Vera, …
    2022

 

  • Inflammation and lipid metabolism as potential biomarkers of memory impairment across type 2 diabetes mellitus and severe mental disorders
    JV Sanchez-Orti, P Correa-Ghisays, V Balanza-Martinez, G Selva-Vera, …
    2023

 

  • MICEmi: A method to identify cognitive endophenotypes of mental illnesses
    P Correa-Ghisays, JV Sanchez-Orti, V Balanza-Martinez, I Fuentes-Dura, …
    2022

 

  • Specific immune-inflammatory profiles and neurocognitive deficits predict illness trajectories in people with type 2 diabetes mellitus or psychiatric disorders
    JV Sanchez-Orti, P Correa-Ghisays, V Balanza-Martinez, G Selva-Vera, …
    2025

 

Conclusion 🎯

Joan Vicent Sánchez Ortí’s dedication to neuroscience and mental health research positions him as an influential figure in the field. His expertise bridges psychology, medicine, and genetics, offering innovative solutions for cognitive disorders. With a strong commitment to improving lives through research, his work has already made a meaningful impact and will continue to shape the future of mental healthcare, neuropsychology, and personalized medicine. As he advances in his career, his passion and contributions will undoubtedly lead to groundbreaking discoveries in cognitive science.

Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo, Xiangya Hospital, Central South University, China.

Dr. Shilin Luo is a leading expert in neuropharmacology and medicinal chemistry, with a strong academic background in traditional Chinese medicine and modern pharmacology. His research focuses on the pathogenesis of neurodegenerative diseases and the development of innovative drug therapies. Through his work at Xiangya Hospital, Central South University, and previous research at Emory University, he has made significant contributions to understanding neurological disorders. His studies on animal models and risk genes have paved the way for novel treatment strategies, earning him international recognition.

Profile

Scopus

Orcid

 

🎓 Early Academic Pursuits

Dr. Shilin Luo’s journey into the world of medical science began with a deep-rooted passion for understanding the complexities of neurological diseases. He earned his Bachelor’s degree in Chinese Materia Medica from Shenyang Pharmaceutical University, where he developed a strong foundation in traditional Chinese medicine and pharmacology. With an insatiable thirst for knowledge, he further pursued a Ph.D. in Medicinal Chemistry at China Pharmaceutical University, specializing in the research of active ingredients in natural products. Under the mentorship of Prof. Wencai Ye, a distinguished scholar, Dr. Luo honed his expertise in medicinal chemistry, paving the way for groundbreaking discoveries in neuropharmacology.

👨‍🎓 Professional Endeavors

To deepen his expertise, Dr. Luo embarked on postdoctoral research at Emory University’s School of Medicine in the Department of Pathology and Laboratory Medicine. Working under the esteemed Prof. Keqiang Ye, he focused on neurobiology and neuropharmacology, contributing significantly to the understanding of neurodegenerative diseases. His research provided novel insights into the molecular mechanisms underlying neurological disorders, positioning him as a leading figure in the field. He later took on a pivotal role as a professor in the Department of Neurology at Xiangya Hospital, Central South University, where he continues to mentor young scientists and advance medical research.

🧪 Contributions and Research Focus

Dr. Luo’s research is primarily dedicated to uncovering the pathogenesis of neurodegenerative diseases and developing therapeutic interventions. His work in animal models of pathogenic and risk genes for neurological disorders has been instrumental in identifying potential drug targets. By integrating traditional Chinese medicine with modern pharmacology, he has contributed to the development of innovative neuroprotective agents. His studies on the molecular mechanisms of neuronal degeneration have led to promising advancements in combating conditions such as Alzheimer’s and Parkinson’s disease.

🏆 Accolades and Recognition

Throughout his career, Dr. Luo has been widely recognized for his groundbreaking contributions to neuropharmacology. His research has been published in high-impact scientific journals, earning him international acclaim. His dedication to scientific excellence has garnered prestigious awards, and he is frequently invited to deliver keynote lectures at global conferences. His work continues to inspire fellow researchers, solidifying his reputation as a distinguished scientist in neurological drug development.

🏰 Impact and Influence

Dr. Luo’s impact extends beyond the laboratory, as he actively contributes to the medical community through mentorship and collaboration. His efforts in integrating traditional Chinese medicinal principles with cutting-edge pharmacological approaches have opened new avenues for drug discovery. His research findings have not only influenced academic discourse but have also laid the groundwork for potential clinical applications, bringing hope to patients suffering from neurodegenerative diseases.

⚛️ Legacy and Future Contributions

As a visionary scientist, Dr. Luo continues to push the boundaries of neurological research. His commitment to translational medicine aims to bridge the gap between laboratory discoveries and clinical applications. By fostering interdisciplinary collaborations and mentoring the next generation of researchers, he is shaping the future of neuropharmacology.

 

Publication

  • Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
    Authors: Yujie Zhang, Jie Chen, Yanru Li, Bin Jiao, Shilin Luo
    Year: 2025

 

  • The role of the probiotic Akkermansia muciniphila in brain functions: insights underpinning therapeutic potential
    Authors: Ruiling Xu, Yuxuan Zhang, Shurui Chen, Yaohui Zeng, Xuan Fu, Ti Chen, Shilin Luo, Xiaojie Zhang
    Year: 2023

 

  • Nonviral delivery systems for antisense oligonucleotide therapeutics
    Authors: Si Huang, Xin-Yan Hao, Yong-Jiang Li, Jun‑Yong Wu, Da-Xiong Xiang, Shilin Luo
    Year: 2022

 

  • The Microglial membrane receptor TREM2 mediates exosome secretion to promote phagocytosis of amyloid‐β by microglia
    Authors: Si Huang, Xiaoli Liao, Junyong Wu, Xiaojie Zhang, Yamin Li, Daxiong Xiang, Shilin Luo
    Year: 2022

 

  • Correction: Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
    Authors: Not explicitly listed
    Year: 2021

 

  • Polygonatum sibiricum Polysaccharides Protect against MPP‐Induced Neurotoxicity via the Akt/mTOR and Nrf2 Pathways
    Authors: Si Huang, Haiyan Yuan, Wenqun Li, Xinyi Liu, Xiaojie Zhang, Daxiong Xiang, Shilin Luo, Guodong Zhang
    Year: 2021

 

  • Bushen-Tiansui Formula Improves Cognitive Functions in an Aβ1–42 Fibril-Infused Rat Model of Alzheimer’s Disease
    Authors: Chenxia Sheng, Panpan Xu, Xinyi Liu, Weijun Peng, Daxiong Xiang, Shilin Luo
    Year: 2020

 

  • Osteogenesis activity of isocoumarin a through the activation of the PI3K-Akt/Erk cascade-activated BMP/RUNX2 signaling pathway
    Authors: Not explicitly listed
    Year: 2019

 

  • Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson’s Disease
    Authors: Shilin Luo, Seong Su Kang, Zhi-Hao Wang, Xia Liu, Julia X Day, Zhiping Wu, Junmin Peng, Daxiong Xiang, Wolfdieter Springer, Keqiang Ye
    Year: 2019

 

  • Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile
    Authors: Not explicitly listed
    Year: 2018

 

Conclusion

Dr. Luo’s unwavering dedication to neurological research continues to shape the future of neuropharmacology. His innovative approach, combining traditional medicinal insights with modern scientific advancements, has the potential to revolutionize drug development for neurodegenerative diseases. As a mentor, researcher, and pioneer in his field, his contributions will leave a lasting impact on both academia and clinical medicine, offering hope for more effective treatments in the years to come.

 

Md Shimul Bhuia | Drug development of neurodegenerative disease | Young Scientist Award 

Mr. Md Shimul Bhuia | Drug development of neurodegenerative disease | Young Scientist Award 

Mr. Md Shimul Bhuia , BioLuster Research Center Limited,  Bangladesh.

An accomplished pharmacist and researcher with expertise in pharmaceutical sciences, molecular docking, and drug development. Awarded the prestigious National Science and Technology Fellowship (NST) in 2023 for contributions to science. Extensive experience includes an internship at Beximco Pharmaceuticals, part-time pharmacy practice, and a full-time role as Deputy Director at BioLuster Research Center. Proficient in advanced software for computational drug design and well-versed in research methodologies. Fluent in Bangla and highly proficient in English, with strong technical and analytical skills.

 

profile

scholor

🎓 Education and Academic Achievements

Master of Pharmacy (M. Pharm.) Department of Pharmacy, Life Science Faculty. Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj-8100, Bangladesh Session: 2020–2021 Course Duration: 1.5 years (3 Semesters)Passing Year: 2022 CGPA: 3.74 (out of 4.00). Bachelor of Pharmacy (B. Pharm.) Department of Pharmacy, Life Science Faculty .Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj-8100, BangladeshSession: 2016–2017  Course Duration: 4 years Hon’s (8 Semesters) Passing Year: 2020 CGPA: 3.45 (out of 4.00)  Higher Secondary Certificate (H.S.C.)  Shahid Bul Bul Govt. College, Pabna Board: Rajshahi Group: Science Passing Year: 2016 GPA: 5.00 (out of 5.00) Secondary School Certificate (S.S.C.) Kamal Pur T.M. High School, Ishwardi, Pabna Board: Rajshahi  Group: Science Passing Year: 2013 GPA: 5.00 (out of 5.00).

🎯 Research Interests

Neurology/Neurodegenerative Diseases , Immunology ,  Cancer Therapy , Toxicology , Molecular Docking , Drug Design and Development via Computational Studies ,Pharmacological Investigation through Preclinical Test Systems , Inflammatory Diseases , Bioinformatics , Anti-cancer Agents

🏆 Honours and Awards

National Science and Technology Fellowship (NST), 2023. Awarded by the Ministry of Science and Technology, Government of Bangladesh

💼 Work Experiences

InternshipBeximco Pharmaceutical Ltd., Squibb Road, Tongi, Bangladesh Duration: November 13, 2022, to November 23, 2022. Pharmacist Worked as a pharmacist at Gafur Chikitsaloi (local pharmacy shop)Employee Status: Part-Researcher Deputy Director, BioLuster Research Center, Gopalganj 8100, Dhaka, Bangladesh Employee Status: Full-time (January 01 – Present)

📚 Publications

 

 Conclusion

With a strong foundation in both clinical practice and academic leadership, Leila Sadati’s career reflects a commitment to advancing healthcare education and patient safety standards. Her contributions in research, curriculum development, and operational management have shaped future medical professionals and enhanced patient care practices. As she continues to innovate and educate, her work remains instrumental in raising the standards of medical and surgical education in Iran and beyond.

 

 

Nawal Al-Subaie | Clinical Neuroscience | Best Researcher Award

Assist Prof Dr. Nawal Al-Subaie | Clinical Neuroscience | Best Researcher Award

Assist Prof Dr. Nawal Al-Subaie,  Princess Noura University, Saudi Arabia

Nawal Al Subaie is a dedicated Clinical Pharmacist with extensive experience in clinical and academic roles at esteemed institutions, including Prince Sultan Military Medical City (PSMMC) and Princess Noura University (PNU). She holds a PhD in Clinical Pharmacy from DMU, UK, and a Master’s in International Practice and Policy from UCL, London. With a career spanning leadership, clinical care, and education, she has made significant contributions to pharmacy practice, quality control, and chronic disease management. Her commitment to continuous learning is reflected in numerous specialized courses and symposiums, along with frequent contributions to global conferences.

 

profile

scholor

🎓 Educational Background

PhD in Clinical Pharmacy,DMU Leicester, United Kingdom.MSc in Clinical Pharmacy (International Practice and Policy)
,UCL School of Pharmacy, London, United Kingdom.Bachelor’s Degree in Hospital Pharmacy,King Saud University, Riyadh, Saudi Arabia.

💼 Working Experience

Deputy in Charge of Pharmacy Division.Family and Community Medicine.Lead Pharmacist. Wazarat Health Centre (WHC).Clinical Pharmacist,Chronic Disease Clinic, WHC.Clinical Instructor / Trainer,Continuous education for pharmacy students at King Saud University, Princess Noura University, Northern Border University.Quality Control Representative Pharmacy, WHC.Part-time Lecturer,Clinical Ocular Pharmacology, King Saud University.JCI Accreditation Awardee,Primary Care Team.In-Charge of Clinical Pharmacist Ambulatory Care Clinics, PSMMC, 2020–2022.Assistant Professor,Princess Noura University (PNU), May 2022 – Present.

🏫 Training Courses / Symposiums

2015 – 2019: PhD Student (Diabetes and Exercise)Pharmacy School, DMU, UK.2014: TOT Course Leicester, UK.2016: Phlebotomy Course Nottingham, UK.2016: First Aid CourseLeicester, UK.2022: ASHP Diabetes Management Certificate Course January – December 2022.

🌍 Conferences Attended & Contributions

2024: Attended the 4th Saudi Society of Clinical Pharmacist Annual International Conference (September).2024: Presented Poster at Dubai International Pharmaceuticals and Technologies Conference.2023: Oral Presentation at Neurology Conference, Dubai (March).2023: Judge, Pharmacy Research Day, PNU Research Center (May).2022: Attended First Saudi Society of Clinical Pharmacist Annual International Conference (September)(and many more from 2000 to 2024)

🤲 Voluntary Work

University orientation for new students, DMU. Diabetes Awareness Day, in collaboration with Diabetes UK. Trained students at DMU on ELISA and Randox machine for blood sample analysis. Assisted pharmacy students with projects and dissertations, DMU

🏅 Professional Memberships

Saudi Commission for Health Specialties (ID: 09-R-P-0295492)

📚 Publications

  1. Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review
    Authors: N. Alsubaie, H.M. Al-Kuraishy, A.I. Al-Gareeb, B. Alharbi, M. De Waard, …
    Year: 2022

 

  1. Discussing Pathologic Mechanisms of Diabetic Retinopathy & Therapeutic Potentials of Curcumin and β-glucogallin in the Management of Diabetic Retinopathy
    Authors: M. Rohilla, S. Bansal, A. Garg, S. Dhiman, S. Dhankhar, M. Saini, S. Chauhan, …
    Year: 2023

 

  1. The Potential Therapeutic Effect of Metformin in Type 2 Diabetic Patients with Severe COVID-19
    Authors: H.M. Al-Kuraishy, A.I. Al-Gareeb, A.A. El Kholy, E. El-Khateeb, A. Alexiou, …
    Year: 2023

 

  1. The Effects of a Combined Exercise Programme Aerobic and Resistance on Blood Glucose, Incretin, Metabolic and Inflammatory Mediators that Could Control the Diabetes and Improve …
    Author: N. Alsubaie
    Year: 2019

 

  1. Corrigendum to “Discussing Pathologic Mechanisms of Diabetic Retinopathy & Therapeutic Potentials of Curcumin and β-glucogallin in the Management of Diabetic Retinopathy”
    Authors: M. Rohilla, S. Bansal, A. Garg, S. Dhiman, S. Dhankhar, M. Saini, S. Chauhan, …
    Year: 2024

 

  1. Impact of Clinical Pharmacist Diabetes Clinic on the Improvement of Health Outcomes in Type 2 Diabetes Subjects
    Authors: N. AlSubaie, M. Alsallal, S. AlTwaijri, A. AlOtaibi, B. AlHarbi, M. AlEissa, …
    Year: 2022

 

  1. The Effects of a Combined Aerobic and Resistance Exercise Programme on Insulin Resistance Among Prediabetes Subjects
    Authors: B. Alharbi, N. Alsubaie, T.S. Sahota, M.J. Taylor
    Year: 2019

 

  1. The Effects of a Combined Exercise Programme (Aerobic and Resistance) on Blood Glucose and Incretin Hormone That Could Control the Diabetes in Type 2 Diabetes
    Authors: N. Alsubaie, B. Alharbi, T.S. Sahota, M.J. Taylor
    Year: 2019

 

  1. The Effects of a Combined Exercise Programme (Aerobic and Resistance) on Blood Glucose, and Incretin Hormone That Could Control the Diabetes in Type 2 Diabetes
    Authors: B.M. Alharbi, N.S. Alsubaie, T.S. Sahota, M.J. Taylor
    Year: 2019

 

  1. The Impact of Moderate Combination Exercise on HbA1c, IL-6, and TNF in Type 2 Diabetic and Non-diabetic Subjects: An Interventional Non-randomized Clinical Trial
    Authors: B. Alharbi, N. Alsubaie, T.S. Sahota, M.J. Taylor
    Year: 2019

 

 Conclusion

Dr. Al Subaie’s career showcases a deep commitment to enhancing patient care, advancing pharmaceutical education, and contributing to international health discussions. Her background in both hands-on clinical care and academic research equips her with a well-rounded perspective, making her a valuable asset in clinical and educational settings alike. She continues to make strides in diabetes management, chronic disease care, and pharmacy education, with her work recognized through multiple presentations, awards, and professional memberships.

 

 

Hamid khan | Molecular and Cellular Neuroscience | Young Scientist Award

Mr.Hamid khan | Molecular and Cellular Neuroscience | Young Scientist Award

Mr. Hamid khan Icahn School of Medicine at Mount Sinai, New York Pakistan

Hamid Khan is a dedicated researcher and educator who recently completed his PhD in Biotechnology, specializing in Human Molecular Genetics. His academic journey includes a strong foundation in biological sciences, evidenced by his educational background ranging from a BSc to a PhD, with a focus on genetic analysis of rare congenital disorders. His doctoral research has provided insights into the genetic basis of autism spectrum disorder (ASD) and oculocutaneous albinism, contributing significantly to the understanding of these conditions.

profile

scholar

🎓 Education

PhD in Biotechnology (Human Molecular Genetics)International Islamic University Islamabad, Pakistan & University of Toronto, Canada (2018-2024).MS/M.Phil in Biotechnology (Human Molecular Genetics)International Islamic University Islamabad, Pakistan (2016-2018).M.Sc in ZoologyHazara University Mansehra, KPK, Pakistan (2011-2013).B.Sc in Biological Science (Botany, Zoology, Chemistry)University of Peshawar, Pakistan (2008-2010).H.S.S.C Pre-Medical
Peshawar Board, Pakistan (2006-2008)S.S.C Science SubjectsPeshawar Board, Pakistan (2004-2006).B.Ed in Education
Sarhad University of Science & Information Technology (2014).CT Certified TeacherAllama Iqbal Open University (2016).

🔬 Research Experience

Researcher at Biomolecular Genetic Engineering Lab, International Islamic University Islamabad (4 years).Research Associate in Pak-US Science and Technology Cooperation Program (1 year).Researcher in MiND Laboratory, Campbell Family Mental Health Research Institute, Toronto, Canada (6 months)

💼 Work Experience

Visiting Lecturer at Department of Biological Sciences, IIUI (3 years).Lecturer at IQRA College of Technology, IIUI (2 years)

 

🛠️ Skills

Laboratory Skills: PCR, NGS data analysis, Microarray, Gene Cloning, Cell Culturing, etc.Computer Skills: Python, Sentieon, Verseq, Exomiser, Excel, PowerPoint, Word.

🏆 Awards

IRSIP Award from the Higher Education Commission (HEC) Pakistan.First position holder in PhD coursework.Selected as Research Associate in a Pak-US project.

🌍 Collaborations

Currently working with three international and several national collaborations.

📚 Publications

  1. Title: Biallelic variants identified in 36 Pakistani families and trios with autism spectrum disorder
    Authors: Hamid Khan, Ricardo Harripaul, Anna Mikhailov, Sumayah Herzi, …
    Year: 2024

 

  1. Title: Elucidating the clinical and genetic spectrum of inositol polyphosphate phosphatase INPP4A-related neurodevelopmental disorder
    Authors: Lettie E Rawlins, Reza Maroofian, Stuart J Cannon, Muhannad Daana, Mina Zamani, Shamsul Ghani, …
    Year: 2024

 

  1. Title: Nigella sativa extract abrogates traumatic brain injury-induced memory impairment in adult mice
    Authors: RU Khan, SM Jawad, MM Kiyani, SA Shah, S Bashir, Hamid Khan
    Year: 2024

 

  1. Title: Mutational spectrum associated with oculocutaneous albinism and Hermansky-Pudlak syndrome in nine Pakistani families
    Authors: J Khan, S Asif, S Ghani, Hamid Khan, MW Arshad, SA Khan, S Lin, EL Baple, …
    Year: 2024

 

  1. Title: An Update on Recent Advancement in Autism Spectrum Disorder Treatment Strategies
    Authors: Hamid Khan, M Uzair, H Riaz, B Khan, MI Shabbir
    Year: 2023

Conclusion

Hamid Khan’s profile illustrates a strong commitment to advancing the field of biotechnology through research and education. His focus on the genetic underpinnings of rare disorders positions him as a valuable contributor to both academic and clinical settings. With a proven track record of research publications and collaborative projects, he is poised to make significant impacts in the realm of human genetics and molecular biology. His dedication to teaching and nurturing student curiosity further underscores his potential as an educator and mentor. As he seeks new opportunities, his combination of technical expertise, research experience, and passion for education will undoubtedly enable him to excel and inspire in any dynamic academic or research environment.